Key Highlights
- On Tuesday, November 17, 2026, shares of SELLAS Life Sciences were trading up 163.69% at USD 19.70, which implies a prior close near USD 7.47 (calculated), after positive Phase 3 REGAL results in acute myeloid leukemia.
- In the Phase 3 REGAL study, galinpepimut-S delivered median overall survival of 24.0 months, compared with 14.7 months on best available treatment, which produced a 0.59 hazard ratio and a p-value of 0.035 on a two-sided test.
- The topline analysis was triggered once the prespecified 80 deaths had occurred among 126 randomized patients, all of whom were in second or later remission and could not undergo a stem cell transplant.
- Cash and cash equivalents stood at USD 134.7 million, with 203,527,833 shares outstanding, as of September 30, 2026, and a Biologics License Application is planned for the first half of 2027.
Positive Phase 3 REGAL Survival Data Drive the Rally
On November 17, 2026, SELLAS Life Sciences (NASDAQ:SLS) said its pivotal REGAL study achieved its overall survival goal. Galinpepimut-S is a Vaccine directed at WT1, a protein found on leukemia cells, and patients on it lived a median of 24.0 months versus 14.7 months in the control group. A hazard ratio of 0.59 translates to a 41% lower risk of death, while the p-value of 0.035 came in under the customary 0.05 mark. Market data show the stock at USD 19.70, up 163.69%, which points to a prior close of about USD 7.47 (calculated). Management called the outcome statistically significant and clinically meaningful.
Inside the REGAL Design and the Best Available Treatment Arm
REGAL is a global, randomized, open-label trial. It enrolled adults whose acute myeloid leukemia reached a second or later complete remission following salvage therapy and who were not candidates for an allogeneic transplant. Of the 126 patients enrolled, half went to the vaccine and half to investigator's choice of best available treatment, a menu that included observation, a hypomethylating agent, venetoclax or low-dose cytarabine. The company noted that prognostic factors were balanced across the arms and that few patients proceeded to transplant, with the numbers even. Tolerability was generally good, with mostly grade 1 or 2 events such as injection-site reactions and no new safety signals.
FDA Plans, Cash on Hand and Risks After a Steep Gain
Management intends to meet the FDA on an accelerated filing strategy and is working toward a Biologics License Application in the first half of 2027. Secondary and other prespecified analyses continue, and a major medical meeting presentation and a Journal paper are planned. In its November 12, 2026 third-quarter report, SELLAS Life Sciences (NASDAQ:SLS) disclosed USD 134.7 million of cash, a net loss of USD 10.1 million and 203.5 million shares outstanding. At USD 19.70, that works out to a Market Value near USD 4.0 billion (calculated), well above the USD 1.52 billion on the screener, which was omitted as inconsistent. The open-label design, a p-value barely under 0.05 and a modest sample are the chief uncertainties, and regulators could ask for more data. A few trades can move such a price, and quoted gains can reverse.
Where Things Stand
The jump came because a pivotal trial turned out positive. SELLAS Life Sciences (NASDAQ:SLS) posted median survival of 24.0 months against 14.7, with a 0.59 hazard ratio and a 0.035 p-value, in a leukemia group that is difficult to treat, and the market repriced the odds of a filing. That does not settle approval: the FDA still has to agree on a path, the full data remain to be presented and USD 134.7 million of cash must cover the filing work. The FDA meeting, the secondary analyses and any financing after such a sharp rally are the next things to watch.
_11_17_2026_18_59_44_560836.jpg)





Please wait processing your request...